# Detective Epidemiologist Investigation: Official H3N2 Influenza Outbreak Reports as of December 5, 2025

## Executive Summary: What’s happening with H3N2 as of Dec 5, 2025

As of early December 2025, the global influenza season is underway and notably earlier than typical in many geographies, with influenza A(H3N2) as the dominant or codominant subtype across large swaths of the Northern Hemisphere. The World Health Organization (WHO) reports that in week 47 (ending Nov 23, 2025) global influenza positivity exceeded 20%, with northern regions showing elevated positivity—exceeding 30% in some countries across Western and Eastern Africa, Northern Europe, and broad sections of Asia. The Southern Hemisphere remains largely at interseasonal levels, with only scattered countries above 10% positivity. These trends mark a clear early-season acceleration compared with recent norms.^[1]

In the United States, the Centers for Disease Control and Prevention (CDC) shows H3N2 accounting for 82.3% of subtyped influenza A viruses in public health laboratories in week 47 and for 73.5% of hospitalizations with subtype information in the FluSurv-NET system since Oct 1. Antigenic characterization indicates potential reduced vaccine match—only one-third of tested H3N2 viruses were well recognized by the 2025–26 vaccine component—yet antiviral susceptibility remains reassuringly high across tested isolates. Cumulative U.S. estimates for the 2025–26 season to date include at least 1.1 million illnesses, 11,000 hospitalizations, and 450 deaths; however, National Center for Health Statistics (NCHS) mortality surveillance data were not available for weeks 39–47.^[2]

The European Centre for Disease Prevention and Control (ECDC) has flagged unusually early increases across the European Union/European Economic Area (EU/EEA), driven by a newly emerged A(H3N2) subclade K (J.2.4.1). Subclade K accounted for roughly one-third of global A(H3N2) sequences (May–November 2025) and nearly half of A(H3N2) sequences in the EU/EEA, with phylogenetic and serological analyses indicating antigenic divergence from the Northern Hemisphere 2025–26 vaccine strain. While this suggests possible reduced vaccine effectiveness against infection, vaccination is still expected to mitigate severe disease.^[3]

England’s surveillance corroborates early-season acceleration with H3N2 dominance and evidence of antigenic mismatch, alongside small numbers of viruses with mutations potentially associated with reduced susceptibility to oseltamivir (NA K249E) and baloxavir (PA I38L). Hospital admissions for H3N2 remain measurable but comparatively modest at this stage.^[4]

Japan has reported an early peak driven by a variant referred to as “Subclade K” in media reporting; available official national surveillance data remain limited at this stage, warranting careful interpretation of non-governmental sources.^[5]

Across the Americas, the Pan American Health Organization (PAHO) has issued guidance emphasizing vigilance and preparedness for concurrent circulation of influenza, respiratory syncytial virus (RSV), and SARS-CoV-2, without发布 detailed H3N2 case numbers in the most recent alert.^[7]

No agency has issued a formal “Disease Outbreak News” item specific to H3N2 as of Dec 5; current information is largely within routine surveillance updates and risk assessments. The most important cross-agency consistency is the early timing, H3N2 predominance, and signals of antigenic divergence. The most material uncertainties are the vaccine effectiveness against subclade K in real-world settings, data gaps in mortality reporting (particularly in the U.S.), and sparse country-level counts across large geographies.

To synthesize the current state, Table 1 provides a consolidated snapshot by geography.

Table 1. At-a-glance H3N2 snapshot as of Dec 5, 2025
| Geography | Dominant strain and signals | Timing vs typical | Key quantitative indicators | Outbreak status | Data gaps |
|---|---|---|---|---|---|
| Global (WHO) | H3N2 predominant or codominant across many Northern Hemisphere regions; elevated positivity (>20% globally; >30% in some countries) | Earlier than usual increases reported by WHO and ECDC | Week 47 global positivity >20%; Northern Hemisphere elevated; Southern Hemisphere largely low | Season underway earlier than typical | Limited country-level counts; Southern Hemisphere mostly interseasonal^[1] |
| United States (CDC) | H3N2 82.3% of subtyped A (week 47); antigenic mismatch signal (33.3% well recognized); no antiviral resistance in tested viruses | Early-season rise; holidays may affect reporting cadence | 1.1M illnesses; 11K hospitalizations; 450 deaths (cumulative); H3N2 73.5% of typed A hospitalizations | Low but increasing activity | NCHS mortality data not available weeks 39–47^[2] |
| EU/EEA (ECDC) | Early increases driven by subclade K (≈33% global, ≈50% EU/EEA of A(H3N2)) | Detections rising ~3–4 weeks earlier than usual | Proportions from sequence data; limited case counts reported | Early-wave concerns | Real-world vaccine effectiveness (VE) data pending^[3] |
| England (UKHSA) | H3N2 dominant; subclade K predominates among characterized viruses; antigenic mismatch noted | Earlier increase | Week 48: 81 H3N2 positives (Respiratory Datamart); 48 hospital admissions; 9 ICU/HDU admissions; 451 H3N2 characterized (420 K-clade) | Moderate early increases | Subtype-specific mortality not reported^[4] |
| Japan (Media citing surveillance) | “Subclade K” reported as driving early peak (sample-based prevalence ≈96% in small set) | Early peak reported | Small-sample surveillance; national count data limited | Early surge signals | Rely on official ministry sources for quantitative updates^[5] |
| Western Pacific (WHO WPRO) | Elevated influenza positivity (sharp increase to ≈35% in week 47) | Early increases in the region | Positivity ≈35% (week 47) | Early acceleration | Limited public breakdown by subtype^[6] |
| Americas (PAHO) | Guidance for co-circulation of influenza, RSV, SARS-CoV-2; no specific H3N2 counts in latest alert | Preparedness focus | Qualitative guidance | Monitoring season onset | Official case counts not provided in alert^[7] |

The implications are clear: public health authorities and healthcare systems should anticipate an early-season wave dominated by H3N2, plan for capacity surges, and maintain high vaccination uptake—especially in older adults and other high-risk groups—despite the mismatch signal. Continued virologic and vaccine effectiveness monitoring is essential to refine forecasts and clinical guidance.

## Methodology & Source Integrity

This investigation synthesizes official surveillance and risk assessments published through Dec 5, 2025, including the WHO global influenza update and Western Pacific regional bulletin, CDC FluView weekly reporting and methods documentation, ECDC threat assessment for the EU/EEA, UKHSA national surveillance for England, PAHO’s epidemiological alert for the Americas, and WHO Western Pacific surveillance. Where official data were inaccessible (notably Canada’s FluWatch+ portal), the report documents the gap and refrains from incorporating non-verifiable content.^[1–7,10–12,14]

We cross-validated quantitative indicators across agencies, noting consistency in timing, subtype predominance, and virologic signals (antigenic characterization, antiviral susceptibility). We used CDC methods documentation to contextualize U.S. surveillance baselines, indicators, and the scope and limitations of FluView systems (clinical laboratories, public health laboratories, FluSurv-NET hospitalizations, mortality surveillance via NCHS, and antiviral resistance testing).^[10] Baseline historical context was drawn from the CDC’s recap of the 2024–25 season.^[14]

Limitations include holiday-related reporting delays, acknowledged data gaps (e.g., U.S. NCHS mortality weeks 39–47), sparse country-level counts, and lagging vaccine effectiveness data for subclade K. We explicitly distinguish official agency reports from media sources (e.g., Japan) and avoid conflating qualitative alerts with count-based outbreak declarations.

## Global Overview (WHO): Activity Levels and H3N2 Predominance Patterns

WHO’s week 47 global update depicts a clear early-season increase across the Northern Hemisphere, with global influenza positivity above 20%. Elevated positivity exceeding 30% was observed in parts of Western and Eastern Africa, Northern Europe, and multiple Asian subregions. Southern Hemisphere countries remained mostly at interseasonal levels, with a few scattered countries above 10% positivity.^[1]

Circulation patterns by subtype show H3N2 predominance or codominance across broad Northern Hemisphere geographies, including Northern Europe, South-West Europe, Western Asia, Southern Asia, Eastern Asia, South-East Asia, parts of South America, Eastern and Southern Africa, and Oceania. H1N1pdm09 predominance was noted in Northern and Middle Africa, while Central America and the Caribbean showed codominance of H3N2 and H1N1pdm09.^[1] In the Western Pacific, WHO’s regional bulletin reported a sharp rise in influenza positivity to approximately 35% in week 47, signaling early acceleration in that transmission zone.^[6]

To illustrate these patterns, Table 2 summarizes positivity and subtype distribution by major geography.

Table 2. WHO Week 47 positivity and subtype patterns
| Geography | Positivity status | Subtype predominance/codominance | Notes |
|---|---|---|---|
| Global | >20% positivity | H3N2 predominant/codominant in many Northern Hemisphere regions | Southern Hemisphere largely low; scattered >10% in热带/temperate zones^[1] |
| Northern Europe | Elevated; some countries >30% | H3N2 predominant | Early increase^[1] |
| Western & Southern Europe | Elevated | H3N2 predominant | Early season^[1] |
| Western Asia | Elevated | H3N2 predominant | Early season^[1] |
| Southern & Eastern Asia | Elevated; some >30% | H3N2 predominant/codominant | Early acceleration^[1] |
| South-East Asia | Elevated | H3N2 predominant | Early acceleration^[1] |
| North Africa | Elevated | H1N1pdm09 predominant | Distinct subtype pattern^[1] |
| Middle Africa | Elevated | H1N1pdm09 predominant | Distinct subtype pattern^[1] |
| Central America & Caribbean | Increasing | Codominant H3N2 and H1N1pdm09 | Early activity^[1] |
| Tropical/Temperate South America | Some elevated | H3N2 predominant | Mixed signals^[1] |
| Eastern & Southern Africa | Scattered elevated | H3N2 predominant | Mixed signals^[1] |
| Oceania | Some elevated | H3N2 predominant | Early signs^[1] |
| Western Pacific (regional) | ≈35% positivity in week 47 | Not broken down by subtype | Early surge^[6] |

The WHO snapshot sets a coherent baseline: H3N2 is leading early-season transmission across much of the Northern Hemisphere, and certain regions are experiencing sharper-than-typical upticks.

## United States (CDC): Virologic, Clinical, and Mortality Indicators

### Virologic surveillance

In week 47 (ending Nov 22, 2025), public health laboratories reported 305 influenza A viruses subtyped, of which 251 (82.3%) were H3N2. Since week 40, public health labs have subtyped 2,159 influenza A viruses, including 1,610 H3N2 (74.6%).^[2] Among 55 H3N2 viruses collected since Sep 28 and characterized genetically, 82% belonged to subclade K, underscoring the rapid rise of this lineage.^[2]

Antigenic characterization revealed a potential vaccine mismatch: of 60 H3N2 viruses tested, only 20 (33.3%) were well recognized by ferret antisera raised against the A/District of Columbia/27/2023-like reference strain representing the 2025–26 Northern Hemisphere vaccine component.^[2] This aligns with ECDC’s assessment of antigenic divergence for subclade K.^[3]

Antiviral susceptibility testing of A/H3 viruses showed no reduced or highly reduced inhibition for oseltamivir, peramivir, or zanamivir (156 viruses tested), and no decreased susceptibility to baloxavir (152 tested).^[2] Table 3 summarizes the U.S. virologic snapshot.

Table 3. CDC Week 47 virologic summary
| Indicator | Week 47 | Cumulative since Week 40 | Notes |
|---|---|---|---|
| Influenza A subtyped (public health labs) | 305 | 2,159 | —^[2] |
| H3N2 count and proportion | 251 (82.3%) | 1,610 (74.6%) | H3N2 dominant^[2] |
| Genetic characterization | 55 H3N2 viruses; 82% subclade K | — | Since Sep 28^[2] |
| Antigenic characterization (vaccine match) | 60 H3N2 tested; 20 (33.3%) well recognized | — | Potential mismatch^[2] |
| Antiviral resistance (A/H3) | 0% reduced susceptibility to neuraminidase inhibitors; 0% decreased susceptibility to baloxavir | — | Tested cohorts: 156 and 152, respectively^[2] |

### Clinical and mortality surveillance

FluSurv-NET hospitalization data show 905 cumulative laboratory-confirmed influenza-associated hospitalizations since Oct 1, including 813 influenza A-associated; among influenza A hospitalizations with subtype information, 122 (73.5%) were H3N2.^[2] CDC’s preliminary cumulative estimates for the 2025–26 season (as of week 47) include at least 1.1 million illnesses, 11,000 hospitalizations, and 450 deaths. Importantly, NCHS mortality surveillance data for weeks 39 through 47 were not available, constraining mortality analysis at this juncture.^[2]

Table 4 consolidates these clinical indicators.

Table 4. CDC clinical and mortality indicators (cumulative, 2025–26)
| Indicator | Value | Period | Notes |
|---|---|---|---|
| Laboratory-confirmed influenza-associated hospitalizations (FluSurv-NET) | 905 | Oct 1–Nov 22 | 813 influenza A; subtype data limited^[2] |
| H3N2 proportion among typed A hospitalizations | 73.5% | Oct 1–Nov 22 | 122 of 166 typed A^[2] |
| Estimated illnesses | ≥1,100,000 | Season-to-date | Preliminary^[2] |
| Estimated hospitalizations | 11,000 | Season-to-date | Preliminary^[2] |
| Estimated deaths | 450 | Season-to-date | Preliminary^[2] |
| NCHS mortality surveillance | Not available | Weeks 39–47 | Holiday-related delays possible^[2] |

Taken together, U.S. data show early-season H3N2 predominance with a mismatch signal but reassuring antiviral susceptibility, and low but rising clinical impact.

## EU/EEA (ECDC): Early Circulation of A(H3N2) Subclade K and Risk Implications

ECDC’s threat assessment highlights unusually early increases in influenza detections in the EU/EEA, with the newly emerged A(H3N2) subclade K (J.2.4.1) detected on all continents and accounting for approximately one-third of global A(H3N2) sequences and nearly half of A(H3N2) sequences in the EU/EEA between May and November 2025.^[3] Phylogenetic and serologic analyses indicate significant divergence from the vaccine strain, suggesting a likely antigenic mismatch; however, vaccination is still expected to provide protection against severe disease. Countries in East Asia experiencing declining epidemics of similar subclade K strains have not reported unusually high disease severity to date.^[3]

ECDC estimates that seasonal influenza in the EU/EEA causes up to 50 million symptomatic cases, 15,000–70,000 deaths, and affects up to 20% of the population annually. While the full public health impact of subclade K remains uncertain, the early timing and mismatch signal warrant heightened vigilance and acceleration of vaccination campaigns.^[3] Table 5 summarizes the risk context.

Table 5. ECDC risk assessment highlights for subclade K
| Dimension | Summary | Evidence |
|---|---|---|
| Circulation timing | Detections rising ~3–4 weeks earlier than usual | Threat assessment brief^[3] |
| Subclade K proportions | ≈33% global; ≈50% EU/EEA of A(H3N2) sequences (May–Nov 2025) | GISAID-based analyses^[3] |
| Vaccine match | Significant divergence from 2025–26 NH vaccine strain; mismatch indicated | Phylogenetic, antigenic, serologic analyses^[3] |
| Expected severity | No unusual severity reported in East Asia declines; EU/EEA impact uncertain | Regional observations^[3] |
| Public health actions | Recommend urgent vaccination uptake; anticipate early-season surge | Seasonal burden context^[3] |

## United Kingdom (UKHSA): H3N2 Circulation, Vaccine Match, and Hospital Admissions

England’s national surveillance shows H3N2 as the majority subtype among circulating viruses, with genetic characterization indicating that most sequenced viruses belong to clade J.2.4.1 (subclade K). In week 48 (Nov 24–30), the Respiratory DataMart system reported 81 H3N2-positive samples out of 4,154 respiratory specimens tested for influenza. Between weeks 40 and 48, 451 H3N2 viruses were genetically characterized, of which 420 were subclade K.^[4]

Hospital admissions remained measurable: 48 new hospital admissions for influenza A(H3N2) across 24 sentinel NHS trusts, and 9 new ICU/HDU admissions across 99 mandatory trusts in week 48.^[4] Antigenic characterization indicated low reactivity of many A(H3N2) viruses (6 of 7 characterized, belonging to K) with post-infection ferret antisera raised against the Northern Hemisphere 2025/26 vaccine H3N2 components, corroborating mismatch signals observed by CDC and ECDC.^[4] Small numbers of H3N2 detections carried NA K249E (reduced oseltamivir susceptibility) or PA I38L (reduced baloxavir susceptibility), with minimal antiviral use reported.^[4]

Table 6. UKHSA week 48 key indicators
| Indicator | Value | Period | Notes |
|---|---|---|---|
| H3N2 positives (Respiratory DataMart) | 81 / 4,154 tested | Week 48 | Influenza positivity increased^[4] |
| H3N2 genetically characterized (cumulative) | 451 total; 420 subclade K | Weeks 40–48 | J.2.4.1 (K) predominance^[4] |
| New hospital admissions (A(H3N2)) | 48 | Week 48 | 24 sentinel NHS trusts^[4] |
| New ICU/HDU admissions (A(H3N2)) | 9 | Week 48 | 99 mandatory NHS trusts^[4] |
| Antigenic characterization | 6/7 (K-clade) low reactivity | Weeks 40–48 | Mismatch signal^[4] |
| Antiviral susceptibility | NA K249E and PA I38L detections (<5 each) | Weeks 40–48 | Low numbers; limited use^[4] |

These indicators confirm early-season H3N2 dominance and antigenic mismatch, with hospital admissions beginning to climb.

## Japan: Early Peak and “Subclade K” Signals

Media reporting in early December described Japan’s flu season arriving early, with surveillance findings attributed to the Japan Institute for Health Security indicating that 22 of 23 recent patient samples (≈96%) were infected with a variant referred to as “Subclade K.” The reports suggested continued spread was expected, but national official count data remain limited within the provided context.^[5] As such, these signals should be treated as provisional and interpreted cautiously until confirmed by official Ministry of Health or equivalent dashboards.^[5]

## Western Pacific (WHO WPRO): Regional Surge Signals

The WHO Western Pacific Regional Office reported a sharp increase in influenza positivity to approximately 35% in week 47. While the bulletin did not provide subtype breakdowns, this magnitude of positivity indicates a pronounced early-season surge in the region and aligns with broader WHO observations of elevated influenza activity across multiple Asian subregions.^[6] Table 7 summarizes the regional indicator.

Table 7. WPRO positivity indicators (week 47)
| Indicator | Value | Period | Notes |
|---|---|---|---|
| Influenza positivity | ≈35% | Week 47 | Sharp increase^[6] |

## Americas (PAHO): Seasonal Transition and Preparedness Guidance

PAHO’s Dec 4, 2025 epidemiological alert focused on the end of the 2025 Southern Hemisphere season and the start of the 2025–26 Northern Hemisphere season. The alert recommended that Member States adjust preparedness plans for potential health service overloads, strengthen surveillance for influenza, RSV, and SARS-CoV-2, ensure vaccination of high-risk groups, and maintain adequate supplies of antivirals and personal protective equipment. The alert did not provide H3N2-specific case counts or hospitalization metrics.^[7] WHO Americas regional updates for week 42 had previously indicated low but rising influenza activity in parts of North America.^[8]

## Cross-Agency Inconsistencies, Gaps, and Timing Anomalies

Several cross-agency consistencies and discrepancies are notable:

- Early timing: Both WHO and ECDC describe earlier-than-usual increases in the Northern Hemisphere, with EU/EEA detections rising three to four weeks ahead of typical seasonality.^[1,3]
- Antigenic mismatch: CDC’s antigenic characterization found only 33.3% of H3N2 viruses well recognized by the 2025–26 vaccine component; UKHSA reported low reactivity in 6 of 7 characterized K-clade viruses; ECDC’s threat assessment concluded significant divergence and likely mismatch for subclade K.^[2–4]
- Mortality reporting gaps: CDC notes that NCHS mortality surveillance data were not available for weeks 39–47, limiting timely assessment of influenza-related mortality.^[2]
- Country-level data sparsity: WHO provides regional and subregional positivity and subtype patterns but limited country-level counts, complicating granular cross-country comparisons.^[1]
- Media vs official sources: Reports about Japan’s early peak and “Subclade K” prevalence are based on media citations of surveillance findings; official national dashboards and counts are needed to validate scale and trajectory.^[5]
- Canada surveillance access: Official national flu surveillance content was inaccessible at the time of review; no quantitative details were incorporated. (PAHO alerts and WHO regional updates offer qualitative context.)^[7,8]

Table 8 inventories these consistencies and discrepancies.

Table 8. Cross-agency comparison
| Dimension | WHO | CDC | ECDC | UKHSA | PAHO | Comment |
|---|---|---|---|---|---|---|
| Timing vs typical | Earlier increases globally | Early-season rise | 3–4 weeks earlier in EU/EEA | Early increase (England) | Monitoring season onset | Consistent early timing^[1–4,7] |
| H3N2 dominance | Predominant/codominant across many Northern regions | 82.3% week 47; 74.6% cumulative | Driven by subclade K | Majority subtype; K predominates | Guidance, no counts | Broad H3N2 dominance^[1–4,7] |
| Antigenic match | Not directly quantified | 33.3% well recognized | Significant divergence; mismatch | Low reactivity (6/7 K) | Not addressed | Mismatch signal consistent^[2–4] |
| Antiviral susceptibility | Not detailed | No resistance in tested A/H3 viruses | Not detailed | Rare mutations (K249E; I38L) | Not addressed | Generally reassuring^[2,4] |
| Mortality data | Not provided | Estimates available; NCHS gaps | Seasonal range provided | Not provided | Not provided | U.S. mortality gap noted^[2,3] |
| Country-level detail | Regional positivity and subtype patterns | State/regional via interactive tools | Sequence proportions | Detailed national indicators | Alert guidance | Data granularity varies^[1–4,7] |

The cumulative picture is one of unusual earliness, H3N2 predominance, and virologic mismatch signals—all consistent across agencies despite differences in reporting cadence and granularity.

## Historical Context and Expected H3N2 Severity Patterns

Historically, H3N2 seasons are associated with higher hospitalization and mortality burdens than H1N1 seasons, particularly in older adults. The CDC’s recap of the 2024–25 season notes that influenza A viruses were predominant, with H1N1 and H3N2 detected at roughly equal levels—a contrast to the early 2025–26 signals of H3N2 dominance.^[14] Scientific and public health commentary across recent seasons has repeatedly emphasized that H3N2 tends to drive more severe outcomes, reinforcing the need for timely vaccination and robust clinical preparedness.^[15,16]

Table 9 outlines selected burden benchmarks for context.

Table 9. Historical burden benchmarks (EU/EEA and U.S.)
| Geography | Season | Symptomatic cases | Deaths | Hospitalization context | Notes |
|---|---|---|---|---|---|
| EU/EEA | Typical season | Up to 50 million | 15,000–70,000 | Not uniformly reported across countries | ECDC seasonal burden range^[3] |
| U.S. | 2024–25 | Not directly comparable to current estimates | Not directly comparable | Highest cumulative hospitalization rate in >10 years (128.3 per 100,000) | CDC historical recap^[14] |

These benchmarks contextualize the early 2025–26 indicators: even if vaccine effectiveness against infection is reduced due to mismatch, the potential for severe outcomes in high-risk populations warrants aggressive prevention.

## Countries Officially Reporting H3N2 Outbreaks and Timing

Using WHO’s regional patterns as the basis for official reporting of elevated H3N2 activity, the following countries/regions are effectively “reporting” H3N2 dominance or elevated influenza positivity consistent with outbreak conditions as of week 47:

- Northern Europe (H3N2 predominant; elevated positivity).^[1]
- Western and Southern Europe (H3N2 predominant; elevated positivity).^[1]
- Western Asia (H3N2 predominant; elevated positivity).^[1]
- Southern and Eastern Asia (H3N2 predominant/codominant; some countries >30% positivity).^[1]
- South-East Asia (H3N2 predominant; elevated positivity).^[1]
- Central America and the Caribbean (codominance; early increases).^[1]
- Eastern and Southern Africa (H3N2 predominant in parts; scattered elevated positivity).^[1]
- Oceania (H3N2 predominant; early signals).^[1]
- Western Pacific region (≈35% positivity; early surge).^[6]

In the U.S., CDC confirms H3N2 dominance among subtyped influenza A and early increases in activity.^[2] In England, UKHSA confirms H3N2 majority subtype with measurable hospital admissions.^[4] PAHO’s alert covers the Americas without specific H3N2 counts, and Japan’s early peak signals are media-cited.^[5,7] The official status of China, Canada, and Australia in this context is limited by sparse public count data within the provided sources, though China CDC’s weekly portal confirms active influenza surveillance programs; country-specific quantitative updates were not extracted here.^[13]

Table 10 maps official signals to status.

Table 10. Official H3N2 outbreak signals by country/region (as of week 47–48, 2025)
| Country/Region | Agency(s) | Status | Indicators |
|---|---|---|---|
| United States | CDC | H3N2 dominant; low but increasing | 82.3% H3N2 (week 47); H3N2 73.5% of hospitalizations; cumulative estimates^[2] |
| England (UK) | UKHSA | H3N2 dominant; early increase | Week 48: 81 H3N2 positives; 48 hospital admissions; 9 ICU/HDU admissions^[4] |
| EU/EEA | ECDC | Early increases; subclade K driving | Sequence proportions (≈33% global; ≈50% EU/EEA); mismatch^[3] |
| Northern Europe | WHO | Elevated positivity; H3N2 predominant | >30% positivity in some countries (week 47)^[1] |
| Western/Southern Europe | WHO | Elevated positivity; H3N2 predominant | Early-season increase^[1] |
| Western Asia | WHO | Elevated positivity; H3N2 predominant | Early-season increase^[1] |
| Southern/Eastern Asia | WHO | Elevated; some >30% positivity | H3N2 predominant/codominant^[1] |
| South-East Asia | WHO | Elevated; H3N2 predominant | Early acceleration^[1] |
| Central America/Caribbean | WHO | Early increases; codominance | H3N2 and H1N1pdm09 codominant^[1] |
| Eastern/Southern Africa | WHO | Scattered elevated; H3N2 predominant | Mixed signals^[1] |
| Oceania | WHO | Some elevated; H3N2 predominant | Early signals^[1] |
| Western Pacific | WHO WPRO | ≈35% positivity (week 47) | Early surge^[6] |
| Japan | Media citing JIHS | Early peak signals | Small-sample “Subclade K” prevalence; await official counts^[5] |
| China | China CDC | Active surveillance; counts not extracted | Weekly portal confirms surveillance; detailed H3N2 counts not retrieved^[13] |
| Canada | PHAC | Portal inaccessible | No counts incorporated; await next available^[7] |
| Australia | DoH | ARSR available; counts not extracted | Official reports exist; counts not retrieved within context^[11] |

## Timeline of Early 2025–26 H3N2 Activity and Progression

The progression of early H3N2 activity can be tracked across weeks 40–49 (early October through early December):

- Weeks 40–45 (early to mid-November): WHO reports rising positivity across Northern Hemisphere regions; U.S. activity remains low but increases; UK notes early circulation signals.^[1,2,4]
- Week 46: U.S. outpatient ILI stable; clinical laboratory positivity remains low.^[9]
- Week 47 (ending Nov 23): Global positivity >20%, with elevated positivity across multiple subregions; U.S. public health labs show H3N2 dominance (82.3%); WPRO positivity ≈35%.^[1,2,6]
- Week 48 (Nov 24–30): UK reports measurable hospital admissions for H3N2; U.S. continues early-season increases with holiday-related reporting adjustments.^[4,9]
- Week 49 (week of Dec 1–7): WHO publishes global update based on week 48; UK publishes week 49 report; U.S. posts week 48 update on Dec 8.^[1,4,10]

Table 11 presents a simple milestone timeline.

Table 11. Milestones and early indicators (weeks 40–49, 2025)
| Week | Milestone | Indicator | Source |
|---|---|---|---|
| 40–45 | Early rise in NH | Elevated positivity; low-level increases | WHO^[1] |
| 46 | U.S. ILI stable | 2.2% outpatient ILI; low clinical lab positivity | CDC week 46^[9] |
| 47 | Global surge signal | >20% global positivity; WPRO ≈35% | WHO^[1,6] |
| 47 | U.S. H3N2 dominant | 82.3% of subtyped A; mismatch signal | CDC^[2] |
| 48 | UK admissions measurable | 48 hospital; 9 ICU/HDU; 81 H3N2 positives | UKHSA^[4] |
| 49 | EU/EEA early increases | Detections ~3–4 weeks early | ECDC^[3] |

The pattern reflects a coordinated early-season acceleration of H3N2 across multiple regions.

## Strategic Implications and Recommendations

Vaccination remains the cornerstone of preparedness. Even with antigenic mismatch signals for H3N2 subclade K, vaccination is still expected to reduce the risk of severe disease and complications, particularly among older adults and those with underlying conditions. Health authorities should intensify outreach to close vaccination gaps and consider programmatic measures to accelerate uptake, especially in settings at risk for rapid spread.^[3]

Surveillance and laboratory capacity must continue to scale to meet the early-season demand. Priorities include:

- Rapid and representative virologic sampling to track clade and subclade dynamics (including subclade K).
- Antigenic characterization and sequencing to monitor drift and mismatch trajectories.
- Antiviral susceptibility surveillance to preserve therapeutic efficacy.
- Real-world vaccine effectiveness studies to quantify protection against infection and severe outcomes.

Clinical readiness requires anticipatory planning for potential surges in outpatient visits and hospitalizations. Hospitals should revisit surge plans, ensure adequate stocks of antivirals and PPE, and implement triage protocols that account for co-circulation of influenza, RSV, and SARS-CoV-2, as emphasized by PAHO.^[7] In the EU/EEA, early increases call for accelerated vaccination without delay and targeted risk communication.^[3]

Risk communication should emphasize the early-season timing, H3N2’s severity profile, and the potential for reduced vaccine effectiveness against infection while reinforcing vaccination’s benefits against severe disease. Messaging should guide the public on timely care-seeking, staying home when ill, and adherence to infection control measures.

Table 12 lays out an actionable checklist.

Table 12. Actionable preparedness checklist
| Domain | Actions | Rationale |
|---|---|---|
| Vaccination | Intensify outreach; remove access barriers; prioritize high-risk groups | Reduce severe outcomes despite mismatch^[3] |
| Surveillance | Scale virologic sampling; antigenic and genetic characterization; antiviral resistance monitoring | Track drift; preserve therapeutics; inform VE studies^[2–4] |
| Clinical readiness | Surge planning; antivirals/PPE inventory; triage protocols | Early wave; co-circulation with RSV/SARS-CoV-2^[7] |
| Data cadence | Ensure timely reporting; document gaps; harmonize indicators | Support real-time decision-making^[2,4] |
| Risk communication | Clear, timely messaging; manage expectations; promote preventive behaviors | Maintain trust; encourage protective actions^[3] |

## Appendices

### Appendix A: Detailed tables and calculations

- U.S. virologic summary (CDC week 47): subtype counts, antigenic characterization, antiviral susceptibility.^[2]
- U.S. clinical and mortality indicators (FluSurv-NET and CDC estimates) with NCHS gap notes.^[2]
- UKHSA week 48 indicators: Respiratory DataMart, genetic characterization, hospital admissions, antigenic characterization, antiviral susceptibility mutations.^[4]
- ECDC risk assessment: subclade K proportions, antigenic divergence, seasonal burden estimates.^[3]
- WHO/WPRO positivity: week 47 global and regional patterns; WPRO ≈35% positivity.^[1,6]
- Historical burden benchmarks: EU/EEA typical ranges; U.S. 2024–25 hospitalization recap.^[3,14]

### Appendix B: Agency data coverage and limitations

Table 13. Data coverage and limitations by agency
| Agency | Coverage | Indicators reported | Notable gaps |
|---|---|---|---|
| WHO | Global (weekly updates) | Positivity, subtype distribution, regional trends | Limited country-level counts; no mortality details^[1] |
| CDC | U.S. national | Subtype counts, hospitalizations, estimates, antigenic characterization, antiviral susceptibility, methods | NCHS mortality data unavailable weeks 39–47; holiday reporting adjustments^[2,10] |
| ECDC | EU/EEA regional | Risk assessment, sequence proportions, mismatch, seasonal burden | Limited case counts; real-world VE data pending^[3] |
| UKHSA | England national | Laboratory counts, genetic characterization, hospital admissions, antigenic characterization, antiviral susceptibility | Subtype-specific mortality not provided^[4] |
| WPRO | Western Pacific regional | Positivity trends (e.g., ≈35% week 47) | No subtype breakdown in bulletin^[6] |
| PAHO | Americas regional | Preparedness guidance | No H3N2-specific counts in latest alert^[7] |
| China CDC | China national | Weekly surveillance portal | Detailed H3N2 counts not extracted in this review^[13] |
| Australia DoH | Australia national | ARSR reports (official) | Counts not retrieved in this review^[11] |
| Canada PHAC | Canada national | FluWatch+ portal | Inaccessible at time of review; counts not incorporated^[7] |

### Appendix C: Reference links and tool outputs

- WHO global and regional bulletins.^[1,6]
- CDC FluView weekly reports and methods; U.S. season recap.^[2,9,10,14]
- ECDC EU/EEA risk assessment.^[3]
- UKHSA national surveillance report (week 49).^[4]
- PAHO epidemiological alert for the Americas.^[7]
- China CDC weekly reports index; WHO WPRO bulletins.^[13,11,12]

## References

[^1]: World Health Organization. Current influenza update. https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-updates/current-influenza-update

[^2]: U.S. Centers for Disease Control and Prevention. Weekly US Influenza Surveillance Report: Key Updates for Week 47, ending November 22, 2025. https://www.cdc.gov/fluview/surveillance/2025-week-47.html

[^3]: European Centre for Disease Prevention and Control. Threat Assessment Brief: Assessing the risk of influenza for the EU/EEA in the context of increasing circulation of A(H3N2) subclade K (November 2025). https://www.ecdc.europa.eu/en/publications-data/threat-assessment-brief-assessing-risk-influenza-november-2025

[^4]: UK Health Security Agency. National flu and COVID-19 surveillance report: 4 December 2025 (Week 49). https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2025-to-2026-season/national-flu-and-covid-19-surveillance-report-4-december-2025-week-49

[^5]: The Japan Times. Japan’s flu season comes early as new variant spreads. https://www.japantimes.co.jp/news/2025/12/02/japan/science-health/flu-season/

[^6]: WHO Western Pacific. Respiratory Viruses Surveillance Bulletin: Epidemiological Week 47. https://www.who.int/westernpacific/publications/m/item/respiratory-viruses-surveillance-bulletin--epidemiological-week-47

[^7]: Pan American Health Organization. Epidemiological Alert: Seasonal Influenza in the Americas Region (End of 2025 Season in the Southern Hemisphere; Start of the 2025–26 Season in the Northern Hemisphere). https://www.paho.org/en/documents/epidemiological-alert-seasonal-influenza-americas-region-end-2025-season-southern

[^8]: Pan American Health Organization. Regional Update, Influenza and Other Respiratory Viruses — Epidemiological Week 42. https://www.paho.org/en/documents/regional-update-influenza-and-other-respiratory-viruses-epidemiological-week-42-24

[^9]: U.S. Centers for Disease Control and Prevention. Weekly US Influenza Surveillance Report: Key Updates for Week 46, ending November 15, 2025. https://www.cdc.gov/fluview/surveillance/2025-week-46.html

[^10]: U.S. Centers for Disease Control and Prevention. U.S. Influenza Surveillance: Purpose and Methods | FluView. https://www.cdc.gov/fluview/overview/index.html

[^11]: WHO Western Pacific. Bi-weekly Influenza Situation Update — Virological Surveillance (October 8, 2025). https://cdn.who.int/media/docs/default-source/wpro---documents/emergency/surveillance/seasonal-influenza/influenza_20251008.pdf?sfvrsn=8044af49_1&download=true

[^12]: WHO Western Pacific. Respiratory Viruses Surveillance Bulletin — Epidemiological Week 45, 2025. https://cdn.who.int/media/docs/default-source/wpro---documents/emergency/surveillance/seasonal-influenza/rvsb_epidemiological-week-45--2025.pdf?sfvrsn=acbb71fe_1

[^13]: China CDC Weekly — Current Volume (7). https://weekly.chinacdc.cn/en/zcustom/currentVolume/1

[^14]: U.S. Centers for Disease Control and Prevention. Influenza Activity in the United States during the 2024–25 Season. https://www.cdc.gov/flu/whats-new/2025-2026-influenza-activity.html

[^15]: Gavi, the Vaccine Alliance. Everything you need to know about “subclade K” flu — and vaccine protection against it. https://www.gavi.org/vaccineswork/everything-you-need-know-about-subclade-k-flu-and-vaccine-protection-against-it

[^16]: Scientific American. How Bad Will Flu Season Be This Year? https://www.scientificamerican.com/article/how-bad-will-flu-season-be-this-year/